Funder
U.S. Food and Drug Administration
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Kesselheim AS, Misono AS, Lee JL, et al. Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease. JAMA J Am Med Assoc. 2008;300(21):2514-2526.
2. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43(10):1583-1597.
3. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000. Ann Intern Med. 2005;142(11):891.
4. The Amundsen Group. Measuring Generic Efficiency in Medicare Part D. Available at: http://phrma-docs.phrma.org/sites/default/files/pdf/Amundsen_PhRMA_LIS_Generic_Efficiency_Summary.pdf Accessed 23 Sept 2020.
5. Chee M, Zhang JX, Ngooi S, Moriates C, Shah N, Arora VM. Generic Substitution Rates of Oral Contraceptives and Associated Out-of-Pocket Cost Savings Between January 2010 and December 2014. JAMA Intern Med. 2018;178(4):561-563.